Vesnarinone suppresses TNF-induced activation of NF-κB, c-Jun kinase, and apoptosis

Journal of Immunology

Volumn 164, Issue 11, 2000, Pages 5815-5825

  Manna, Sunil K ^a   Aggarwal, Bharat B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PIPERANOMETOZINE; QUINOLINE DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR;

APOPTOSIS; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; GENE EXPRESSION; GROWTH REGULATION; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL;

EID: 0034123507     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.11.5815     Document Type: Article

References (75)

1. Cohn, J. N., S. O. Goldstein, B. H. Greenberg, B. H. Lorell, R. C. Bourge, B. E. Jaski, S. O. Gottlieb, F. McGrew III, D. L. DeMets, and B. G. White. 1998. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure: Vesnarinone Trial Investigators. N. Engl. J. Med. 339:1810.
2. Sasayama, S., A. Matsumori, Y. Matoba, S. Matsui, T. Yamada, T. Shioi, Y. Sato, K. Doyama, and C. Kishimoto. 1996. Immunomodulation: a new horizon for medical treatment of heart failure. J. Cardiac Failure 2:S287.
3. Matsui, S., A. Matsumori, Matoba, A. Uchida, and Sasayama. 1994. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone; suppression of natural killer cell activity and tumor necrosis factor-α production. J. Clin. Invest. 94:1212.
4. Shioi, T., A. Matsumori, S. Matsui, and S. Sasayama. 1994. Inhibition of cytokine production by a new inotropic agent, vesnarinone, in human lymphocytes, T cell line, and monocytic cell line. Life Sci. 54:PL11.
5. Sato, Y., A. Matsumori, and S. Sasayama. 1995. Inotropic agent vesnarinone inhibits cytokine production and E-selectin expression in human umbilical vein endothelial cells. J. Mol. Cell. Cardiol. 27:2265.
6. Sasayama, S., and A. Matsumori. 1996. Vesnarinone: a potential cytokine inhibitor. J. Cardiac Failure 2:251.
7. Kambayashi, T., N. Mazurek, C. O. Jacob, N. Wei, M. Fong, and G. Strassmann. 1996. Vesnarinone is a selective inhibitor of macrophage TNF release. Int. J. Immunopharmacol. 18:371.
8. Jiang, H., B. Bielekova, H. Okazaki, K. Clarence-Smith, K. P. Johnson, G. Bergey, R. Martin, and S. Dhib-Jalbut. 1999. The effect of vesnarinone on TNF-α production in human peripheral blood mononuclear cells and microglia: a preclinical study for the treatment of multiple sclerosis. J. Neuroimmunol 97: 134.
9. Matsumori, A. 1997. The use of cytokine inhibitors: a new therapeutic insight into heart failure. Int. J. Cardiol. 62(Suppl. 1):S3.
10. Suzumura, A., and M. Sawada. 1999. Effects of vesnarinone on cytokine production and activation of murine microglia. Life Sci. 64 :1197.
11. Hattori, Y., S. So, S. Hattori, K. Kasai, and S. Shimoda. 1995. Vesnarinone inhibits induction of nitric oxide synthase in J774 macrophages and rat cardiac myocytes in culture. Cardiovas. Res. 30:187.
12. Matsumori, A., I. Okada, T. Shioi, Y. Furukawa, T. Nakamura, K. Ono, A. Iwasaki, and S. Sasayama. 1996. Inotropic agents differentially inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophages. Life Sci. 59:PL121.
13. Kurosaki, K., U. Ikeda, Y. Maeda, M. Shimpo, S. Ueno, and K. Shimada. 1998. Effects of vesnarinone on nitric oxide synthesis in rat cardiac myocytes. Cardiovas. Res. 38:192.
14. Yokoyama, H., R. Momeni, C. Goldstein, M. Mohiuddin, Z. Shen, B. S. Fyfe, G. J. Whitman, and V. J. DiSesa. 1996. Effects of vesnarinone, a novel orally active inotropic agent with an immunosuppressive action, on experimental cardiac transplantation in rats. Transplantation 62:1540.
15. Kitakaze, M., M. Fong, M. Yoshitake, T. Minamino, K. Node, Y. Okuyama, N. Terada, T. Hirozane, A. Matsumori, Y. Furukawa, S. Matsui, et al. 1997. Prolongation of murine cardiac allograft survival with vesnarinone. J. Mol. Cell Cardiol. 29:67.
16. Takeuchi, K., P. J. del Nido, A. E. Ibrahim, H. Cao-Danh, I. Friehs, P. Glynn, D. Poutias, D. B. Cowan, and F. X. McGowan, Jr. 1999. Vesnarinone and amrinone reduce the systemic inflammatory response syndrome. J. Thorac. Cardiovas. Surg. 117:375.
17. Busch, F. W., A. Tillmann, E. W. Becker, M. Owsianowski, and P. A. Berg. 1992. The inhibitory effects of a positive inotropic quinolinone derivative, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (OPC-8212), on bone-marrow progenitor cells and peripheral lymphocytes. Eur. J. Clin. Pharmacol. 42:629.
18. Nabeshima, R., S. Aizawa, M. Nakano, K. Toyama, K. Sugimoto, A. Kaidow, T. Imai, and H. Handa. 1997. Effects of vesnarinone on the bone marrow stromal cell-dependent proliferation and differentiation of HL60 cells in vitro. Exp. Hematol. 25:509.
19. Lazarus, D. D., T. Kambayashi, M. Yato-Kioka, H. Baumann, C. O. Jacob, and G. Strassmann. 1997. Vesnarinone inhibits immune-mediated but not Fas (CD95) agonist-mediated hepatic injury. Int. J. Immunopharmacol. 19:49.
20. Maruyama, I., Y. Maruyama, T. Nakajima, I. Kitajima, M. Osame, J. Q. Zhao, I. S. Chen, S. Nakai, M. Ikeda, Y. Yabu-uchi, et al. 1993. Vesnarinone inhibits production of HIV-1 in cultured cells. Biochem. Biophys. Res. Commun. 195: 1264.
21. Matsui, S., A. Matsumori, and S. Sasayama. 1994. Vesnarinone prolongs survival and reduces lethality in a murine model of lethal endotoxemia. Life Sci. 55:1735.
22. Kawai, K., Y. Konishi, K. Izumi, M. Sato, M. Adachi, and M. Hozumi. 1998. Enhancement of anticancer effects of radiation and conventional anticancer agents by a quinolinone derivative, vesnarinone: studies on human gastric cancer tissue xenografts in nude mice. Anticancer Res. 18:405.
23. Yokozaki, H., R. Ito, S. Ono, K. Hayashi, and E. Tahara. 1999. Effect of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-pirjerazinyl]-2(1H)- quinolinone(vesnarinone) on the growth of gastric cancer cell lines. Cancer Lett. 140:121.
24. Fujita, M., T. Tsuchida, T. Fujita, and K. Higashino. 1999. Effects of quinolinone derivative, vesnarinone, in combination with irradiation on human lung cancer cell lines. Oncol. Rep. 6:353.
25. Honma, Y., Y. Yamamoto-Yamaguchi, and Y. Kanatani. 1999. Vesnarinone and glucocorticoids cooperatively induce G1 arrest and have an anti-tumour effect on human non-small cell lung carcinoma cells grown in nude mice. Br. J. Cancer. 80:96.
26. Kubo, K., Y. Matsuzaki, A. Kato, S. Terai, and K. Okita. 1999. Antitumor effect of vesnarinone on human hepatocellular carcinoma cell lines. Int. J Oncol. 14:41.
27. Sato, M., K. Harada, T. Bando, T. Shirakami, K. Nakashiro, H. Yoshida, S. Nakai, K. Kawai, and M. Adachi. 1995. Characteristics of antitumor activity of 3,4-dihydro-6-[4-(3, -dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (vesnarinone) against a human adenoid squamous carcinoma-forming cell line grown in athymic nude mice. Cancer Lett. 91:1.
28. Yoneda, K., T. Yamamoto, E. Ueta, and T. Osaki. 1998. Induction of cyclin-dependent kinase inhibitor p21 in vesnarinone-induced differentiation of squamous cell carcinoma cells. Cancer Lett. 133:35.
29. Tanaka, S., K. Kawai, S. Nakai, M. Adachi, and T. Hori. 1999. Apoptosis-inducing activity and growth suppression by vesnarinone on human glioma transplanted in nude mice. Neurolog. Res. 21:409.
30. Nara, N., H. Kurokawa, S. Tohda, J. Tomiyama, K. Nagata, and S. Tanikawa. 1997. Effect of vesnarinone, a quinolinone derivative, on the growth of leukemic blasts in acute myelogenous leukemia. Exp. Hematol 25:199.
31. Fujiwara, H., N. Arima, H. Otsubo, K. Matsushita, S. Hidaka, K. Arimura, T. Kukita, K. Yamaguchi, and H. Tanaka. 1997. Vesnarinone exhibits antitumor effect against myeloid leukemia cells via apoptosis. Exp. Hematol. 25:1180.
32. Nio, Y., H. Ohmori, Y. Minari, N. Hirahara, S. Sasaki, M. Takamura, and K. Tamura. 1997. A quinolinone derivative, vesnarinone (OPC-8212), significantly inhibits the in vitro and in vivo growth of human pancreatic cancer cell lines. Anti-Cancer Drugs 8:686.
33. Baeuerle, P. A., and V. R. Baichwal. 1997. NF-κB as a frequent target for immunosuppressive and anti-inflammatory molecules Adv. Immunol. 65:111.
34. Pahl, H. L. 1999. Activators and target genes of Rel/NF-κB transcription factors. Oneogrne 18:6853.
35. Malinin, N. L., M. P. Boldin, A. V. Kovalenko, and D. Wallach. 1997 MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1. Nature 385:540.
36. Darnay, B., J. Ni, P. A. Moore, and B. B. Aggarwal. 1999. Activation of NF-κB by RANK requires TRAF6 and NF-κB-inducing kinase (NIK): identification of a novel TRAF6 interaction motif. J. Biol. Chem. 274:7724.
37. Chaturvedi, M. M., R. LaPushin, and B. B. Aggarwal. 1994. Tumor necrosis factor and lymphotoxin: qualitative and quantitative differences in the mediation of early and late cellular responses. J. Biol. Chem. 269:14575.
38. Manna, S., H. J. Zhang, T. Yan, L. W. Oberley, and Aggarwal B. B. 1998. Overexpression of Mn-superoxide dismutase suppresses TNF induced apoptosis and activation of nuclear transcription factor-κB and activated protein-1. J. Biol. Chem. 273:13245.
39. Manna, S. K., A. Mukhopadhyay, N. T. Van, and B. B. Aggarwal. 1999. Silymarin suppresses TNF-induced activation of nuclear transcription factor-κB, c-Jun N-terminal kinase and apoptosis J. Immunol. 163:6800.
40. Manna, S., and B. B. Aggarwal. 1999. Immuntisuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-κB activation and gene expression. J. Immunol. 162:2095.
41. Finco, T. S., A. A. Beg, and A. S. Baldwin. 1994. Inducible phosphorylation of IκB α is not sufficient for its dissociation from NF-κB and is inhibited by protease inhibitors. Proc. Natl. Acad. Sci. USA 91:11884.
42. Mahon, T. M., and L. A. O'Neill. 1995. Studies into the effect of the tyrosine kinase inhibitor herbimycin A on NF-κB activation in T lymphocytes: evidence for covalent modification of the p50 subunit. J. Biol. Chem. 270:28557.
43. Natarajan, K., S. Singh, T. R. Burke, Jr., D. Grunberger, and B. B. Aggarwal. 1996. Caffeic acid phenethyl ester (CAPE) is a potent and specific inhibitor of activation of nuclear transcription factor NF-κB. Proc: Natl. Acad. Sci. USA 93:9090.
44. Bonizzi, G., J. Piette, M. P. Merville, and V. Bours. 1997. Distinct signal transduction pathways mediate nuclear factor-κB induction by IL-1β in epithelial and lymphoid cells J. Immunol. 159:5264.
45. 2 in NF-κB activation by either cytokine in both primary and transformed endothelial cells. J. Biol. Chem. 272:25941.
46. Li, N., and M. Karin. 1998. Ionizing radiation and short wavelength UV activate NF-κB through two distinct mechanisms. Proc. Natl. Acad. Sci. USA 95:13012.
47. Nasuhara, Y., I. M. Adcock, M. Catley, P. J. Barnes, and R. Newton. 1999. Differential IκB kinase activation and IκBα degradation by interleukin-1β and tumor necrosis factor-α in human U937 monocytic cells: evidence for additional regulatory steps in κB-dependent transcription. J. Biol. Chem. 274:19965.
48. Hsu, H., H. B. Shu, M. G. Pan, and D. V. Goeddel. 1996. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84:299.
49. Simeonidis, S., D. Stauher, G. Chen, W. A. Hendrickson, and D. Thanos. 1999. Mechanisms by which IKB proteins control NF-κB activity. Proc. Natl. Acad. Sci. USA 96:49.
50. Karin, M. 1995. The regulation of AP-1 activity by mitogen-activated protein kinases. J. Biol. Chem. 270:16483.
51. Kambayashi, T., and M. Hori. 1997. Vesnarinone inhibits adenosine uptake in endothelial cells, smooth muscle cells and myocytes, and mediates cytoprotection. J. Mol. Cell. Cardiol. 29:3413.
52. Kumakura, T., K. Takase, N. Terada, and E. W. Gelfand. 1995. Vesnarinone inhibits nucleoside and nucleobase transport. Life Sci 57:PL75.
53. Stancovski, I., and D. Baltimore. 1997. NF-κB activation: the IκB kinase revealed? Cell 91:299.
54. Lee, F. S. J., J. Hagler, Z. J. Chen, and T. Maniatis. 1997. Activation of the IκBα kinase complex by MEKK1, a kinase of the JNK pathway. Cell 88:213.
55. Hirano, M., S. Osada, T. Aoki, S. Hirai, M. Hosaka, J. Inoue, and S. Ohno. 1996. MEK kinase is involved in tumor necrosis factor α-induced NF-κB activation and degradation of IκB-α. J. Biol. Chem. 271:13234.
56. Ninomiya-Tsuji, J., K. Kishimoto, A. Hiyama, J.-I. Inoue, Z. Cao, and K. Matsumoto. 1999. The kinase TAKI can activate the NIK-IκB as well as the MAP kinase cascade in the IL-1 signaling pathway. Nature 398:252.
57. Cohen, L., W. J. Henzel, and P. A. Baeuerle. 1998. IKAP is a scaffold protein of the IκB kinase complex. Nature 395:292.
58. Zhao, Q., and F. S. Lee. 1999. Mitogen-activated protein kinase/ERK kinase kinases 2 and 3 activate nuclear factor-κB through IκB kinase-α and IκB kinase-β. J. Biol. Chem. 274:8355.
59. Ueda, S., H. Nakamura, H. Masutani, T. Sasada, S. Yonehara, A. Takabayashi, Y. Yamaoka, and J. Yodoi. 1998. Redox regulation of caspase-3 (-like) protease activity: regulatory roles of thioredoxin and cytochrome c. J. Immunol. 161:6689.
60. Buttke, T. M., and P. A. Sandstrom. 1994. Oxidative stress as a mediator of apoptosis. Immunol. Today 15:7.
61. Verheij, M., R. Bose, X. H. Lin, B. Yao, W. D. Jarvis, S. Grant, M. J. Birrer, E. Szabo, L. I. Zon, J. M. Kyriakis, et al. 1996. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 380:75.
62. Guo, Y. L., K. Baysal, B. Kang, L. J. Yang, and J. R. Williamson. 1998. Correlation between sustained c-Jun N-terminal protein kinase activation and apoptosis induced by tumor necrosis factor-α in rat mesangial cells. J. Biol. Chem. 273:4027.
63. Roulston, A., C. Reinhard, P. Amiri, and L. T. Williams. 1998. Early activation of c-Jun N-terminal kinase and p38 kinase regulate cell survival in response to tumor necrosis factor alpha. J. Biol. Chem. 273:10232.
64. Kumar, A., and B. B. Aggarwal. 1999. Assay for redox sensitive kinases. In Methods in Enzymology. Vol. 300. L. Packer, ed. Academic Press, New York, p. 339.
65. Cai, Z., M. Korner, N. Tarantino, and S. Chouaib. 1997. IκB α overexpression in human breast carcinoma MCF7 cells inhibits nuclear factor-κB activation but not tumor necrosis factor-α-induced apoptosis. J. Biol. Chem. 272:96.
66. Natoli, G., A. Costanzo, F. Guido, F. Moretti, A. Bernardo, V. L. Burgio, C. Agresti, and M. Levrero. 1998. Nuclear factor κB-independent cytoprotective pathways originating at tumor necrosis factor receptor-associated factor 2. J. Biol. Chem. 273:31262.
67. Bessho, R., K. Matsubara, M. Kubota, K. Kuwakado, H. Hirota, Y. Wakazono, Y. W. Lin, A. Okuda, M. Kawai, R. Nishikomori, et al. 1994. Pyrrolidine dithiocarbamate, a potent inhibitor of nuclear factor κB (NF-κB) activation, prevents apoptosis in human promyelocytic leukemia HL-60 cells and thymocytes. Biochem. Pharmacol. 48:1883.
68. Abbadie, C., N. Kabrun, F. Bouali, J. Smardova, D. Stehelin, B. Vandenbunder, and P. J. Enrietto. 1993. High levels of c-rel expression are associated with programmed cell death in the developing avian embryo and in bone marrow cells in vitro. Cell 75:899.
69. Manna, S. K., M. T. Kuo, and B. B. Aggarwal. 1999. Overexpression of y-glutamylcysteine synthetase abolishes tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-κB and activator protein-1 Oncogene 18:4371.
70. Xu, X., J. W. Williams, H. Gong, A. Finnegan, and A. S. F. Chong. 1996. Two activities of immunosuppressive metabolite of leflunomide. A771726: inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation Biochem. Pharmacol. 52:527.
71. Torre-Amione, G., B. Bozkurt, A. Deswal, and D. L. Mann. 1999. An overview of tumor necrosis factor a and the failing human heart. Curr. Opin. Cardiol. 14:206.
72. Wong, S. C., M. Fukuchi, P. Melnyk, I. Rodger, and A. Giaid. 1998. Induction of cyclooxygenase-2 and activation of nuclear factor-κB in myocardium of patients with congestive heart failure. Circulation 98:100.
73. Sabbah, H. N., V. G. Sharov, and S. Goldstein. 1998. Programmed cell death in the progression of heart failure. Ann. Med. 30(Sunpl. 1):33.
74. Ruffolo, R. R., Jr., and G. Z. Feuerstein. 1998. Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. J. Cardiovasc. Pharmacol. 32:S22.
75. Kopp, E., and S. Ghosh. 1994. Inhibition of NF-κB by sodium salicylate and aspirin Science 265:956.